Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Epstein-Barr-negative MS: a true phenomenon?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Monozygotic twins discordant for narcolepsy type 1 and multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Illegal cannabis use is common among Danes with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: We aimed to investigate the role of oxidative stress in the progression of multiple sclerosis (MS).

METHODS: We determined by liquid chromatography-tandem mass spectrometry nonenzymatic (F2-isoprostanes) and enzymatic oxidation products of arachidonic acid (prostaglandin F2α [PGF2α]) in plasma and CSF of 45 controls (other neurologic disease [OND] with no signs of inflammation) and 62 patients with MS. Oxidation products were correlated with disease severity and validated biomarkers of inflammation (chemokine ligand 13; matrix metalloproteinase-9; osteopontin) and axonal damage (neurofilament light protein).

RESULTS: Compared with OND controls, plasma concentrations of F2-isoprostanes and PGF2α were significantly lower in patients with progressive disease, and decreased with increasing disability score (Expanded Disability Status Scale). In contrast, CSF concentrations of PGF2α, but not F2-isoprostanes, were significantly higher in patients with progressive disease than OND controls (p < 0.01). The content of PGF2α in CSF increased with disease severity (p = 0.044) and patient age (p = 0.022), although this increase could not be explained by age. CSF PGF2α decreased with natalizumab and methylprednisolone treatment and was unaffected by the use of nonsteroidal anti-inflammatory drug in secondary progressive MS. CSF PGF2α did not associate with validated CSF markers of inflammation and axonal damage that themselves did not associate with the Expanded Disability Status Scale.

CONCLUSIONS: Our data suggest that MS progression is associated with low systemic oxidative activity. This may contribute to immune dysregulation with CNS inflammation accompanied by increased local cyclooxygenase-dependent lipid oxidation.

Original languageEnglish
JournalNeurology® neuroimmunology & neuroinflammation
Volume3
Issue number4
Pages (from-to)e256
ISSN2332-7812
DOIs
Publication statusPublished - Aug 2016

    Research areas

  • Journal Article

ID: 49730260